Shreis Scalene Group Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Shreis Scalene Group's estimated annual revenue is currently $1.6M per year.(i)
  • Shreis Scalene Group's estimated revenue per employee is $155,000

Employee Data

  • Shreis Scalene Group has 10 Employees.(i)
  • Shreis Scalene Group grew their employee count by 11% last year.

Shreis Scalene Group's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is Shreis Scalene Group?

The Shreis Scalene Group of Therapeutic and Diagnostic medical device companies is head-quartered in Montgomery County, MD. Together with the Inventor and Technology partner, Dr. Rajah Vijay Kumar, the Shreis Scalene Group is bringing novel, non-invasive, engineering solutions to human health problems. These include the CYTOTRON® with US-FDA Breakthrough Designation granted for solid tumors of the Breast, Liver and Pancreas (among other solid tumors clinically validated in off-shore clinical studies); tissue regeneration (in musculoskeletal disorders, degenerative respiratory disorders, wound healing etc.); the CELLFORN® for safe, non-invasive cancer drug delivery, and the HAEMOSEIS-256® - a diagnostic cardiovascular disease detection device; for North and South American markets, including Mexico and the Caribbean. Shreis’ mission is to introduce leading-edge platform technologies that will impact the survivorship experience with quality of life, and continue to offer global solutions for safer, patient-centric, affordable healthcare.

keywords:N/A

N/A

Total Funding

10

Number of Employees

$1.6M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M100%N/A
#2
$0.9M10-9%N/A
#3
$1.6M1011%N/A
#4
$1.6M100%N/A
#5
$0.9M1011%N/A